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ABSTRACT
Bloodstream infection caused by vancomycin-resistant enterococcus (VRE) is associated with very high
mortality among allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. However, it remains
unclear whether VRE bloodstream infection directly causes mortality in the early posttransplant period or is
simply a marker of poor outcome. To determine the risk factors for VRE bloodstream infection and its effect
on outcome, we followed 92 patients screened for stool colonization by VRE upon admission for alloHSCT.
Patient records were reviewed to determine outcomes, including mortality and microbiologic failure. Colo-
nization by VRE was extremely common, occurring in 40.2% of patients. VRE bloodstream infection developed
in 34.2% of colonized patients by day 35, compared to 1.8% without VRE colonization (P < .01). VRE
bloodstream infection was associated with a significant decrement in survival and frequent microbiologic
failure, despite treatment with linezolid and/or daptomycin. Five (35.7%) of 14 patients with VRE bloodstream
infection had attributable mortality or contributing mortality from the infection. Strain typing by pulsed-field
gel electrophoresis identified 9 different VRE strains among the 37 colonized patients and 5 patients with
different strains recovered from the stool and the blood. In conclusion, stool screening effectively identified
patients at extremely high risk for VRE bloodstream infection. The high mortality of VRE in the early
posttransplant period supports the use of empiric antibiotics with activity against VRE during periods of fever
and neutropenia in colonized patients.
© 2007 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
Enterococci are commensal ﬂora of the human
astrointestinal tract. Although capable of causing
astrointestinal, genitourinary, and endovascular in-
ections, enterococci were previously considered to
ave limited pathogenicity [1]. The unique nature of
ancomycin-resistant enterococci (VRE) became ap-
arent soon after the ﬁrst VRE isolates were described
n 1987. By the mid-1990s, over 25% of enterococci
ausing bloodstream infections in the United States
ere resistant to vancomycin [2] and VRE are now an lmportant cause of hospital-acquired infections glo-
ally [1,3,4]. The vast majority of VRE infections in
he United States are caused by Enterococcus faecium,
ith a smaller fraction caused by E. faecalis, E. avium,
nd other species [5]. The enhanced virulence of van-
omycin-resistant E. faecium, compared to antibiotic-
usceptible enterococci, is likely to be mediated by a
athogenicity island that includes the esp, hyl, and acm
enes [4,6]. In a recent report, hospital-derived van-
omycin-resistant E. faecium from 5 continents were
ound to be primarily derived from a single clonal
ineage, arguing that this organism is highly adapted
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D. M. Weinstock et al.616or success in hospital environments and has under-
one a remarkably rapid, global dissemination [4]. In
ddition, a meta-analysis of enterococcal infections
ecently demonstrated that bloodstream infection by
ancomycin-resistant isolates is associated with in-
reased mortality, compared to infection with vanco-
ycin-susceptible isolates [7,8].
Immunocompromised patients are at especially
igh risk for VRE bloodstream infection [9-12]. Col-
nization of the gastrointestinal tract with VRE may
recede bloodstream infection in these patients, either
hrough nosocomial acquisition or as a result of ex-
ensive exposure to broad-spectrum antibacterial an-
ibiotics [13,14]. Among patients colonized with VRE,
ucosal damage from high-dose chemotherapy may
ermit enteric VRE to seed the portal and systemic
irculations.
In several reports, VRE bloodstream infection was
ssociated with very high mortality among hemato-
oietic stem cell transplant (HSCT) recipients [15-
8]. Avery et al [16] reported 100% mortality among
2 allogeneic HSCT (alloHSCT) recipients who de-
eloped VRE bloodstream infection between 1997
nd 2003. In a study from Memorial Sloan-Kettering
ancer Center (MSKCC) between 1993 and 1996
17], 17 (85%) of 20 patients with VRE bloodstream
nfection died. Despite the high mortality, some au-
hors have questioned whether VRE infection is a true
ause of adverse outcome among immunocompro-
ised patients or simply a marker of poor prognosis
16,19]. It also remains unclear whether the use of
ewer agents, such as linezolid and daptomycin, will
educe the mortality from VRE bloodstream infection
n alloHSCT recipients.
We sought to determine whether routine screen-
ng of alloHSCT recipients for stool colonization with
RE effectively identiﬁes patients at high risk for
RE bloodstream infection in the early posttransplant
eriod, offering the potential for targeted empiric or
rophylactic strategies. In addition, we reviewed the
utcomes of alloHSCT recipients with VRE blood-
tream infection within 35 days after transplant, to
etermine the efﬁcacy of newer antimicrobials in this
opulation.
ATIENTS AND METHODS
Patient records and the alloHSCT database were
eviewed to identify patients admitted for an initial
lloHSCT between August 2004 and February 2006.
outine isolation for all patients undergoing al-
oHSCT at MSKCC includes a private room, gloves,
nd mask. Gowns are added to precautions for pa-
ients colonized by VRE. Since August 2004, patients
dmitted for alloHSCT underwent screening for VRE
olonization by stool culture. Further routine stool
ultures were not performed, although subsequent 9tool cultures were obtained in patients with diarrhea
r upon transfer to the intensive care unit. Antibacte-
ial prophylaxis was not given for the ﬁrst 19 months
f the study period. Because of an unexpectedly high
ate of viridans Streptococci infections among al-
oHSCT recipients at our center [20], empiric vanco-
ycin was given to patients undergoing myeloablative
lloHSCT during the ﬁnal 3 months of the study
eriod. No enteral or topical antibiotics were rou-
inely administered as prophylaxis. T cell depletion
as performed by either soybean lectin agglutination
r CD34 selection (Isolex 300i; Nexell Therapeutics,
rvine, CA), in each case followed by rosetting with
heep erythrocytes [21].
Vancomycin and linezolid susceptibility were de-
ermined using the MicroScan Dried Gram-Positive
anel (Dade Behring). Daptomycin susceptibility was
erformed by Etest (AB Biodisk, Piscataway, NJ).
ulse-ﬁeld gel electrophoresis (PFGE) was performed
fter SmaI digest, as previously described [22].
Associations between demographic and treatment
actors and (1) VRE colonization determined at trans-
lant, and (2) VRE bloodstream infection among col-
nized patients were examined using Fisher’s exact
est for categoric variables and Wilcoxon rank sum
est for continuous variables. Examined demographic
nd treatment factors included patient age, sex, un-
erlying disease, time from diagnosis to transplant,
revious cycles of chemotherapy, myeloablative versus
onmyeloablative preparative regimen, use of total
ody irradiation 2 Gy in the preparative regimen,
llograft T cell depletion, bone marrow versus periph-
ral blood stem cell allograft, and matched sibling
ersus alternative donor. Survival was compared using
Cox proportional hazards model with time-depen-
ent covariates for colonization and infection.
ESULTS
requent Stool Colonization Prior to alloHSCT
During the study period, 92 patients (Table 1)
nderwent screening for stool colonization. Thirty-
even (40.2%) of the 92 patients had VRE stool col-
nization, including 2 with colonization identiﬁed be-
ore admission, 25 with VRE isolated from the initial
tool culture after admission, and 10 who had negative
nitial stool cultures then had VRE isolated from sub-
equent cultures. Patients with acute leukemia or re-
ractory anemia with excess blasts (RAEB) had an
ncreased risk for VRE colonization, compared with
ther underlying diseases (P  .03). No other demo-
raphic, disease, or treatment-related factors were as-
ociated with VRE colonization.
loodstream Infections
There were 34 bloodstream infections among the
2 patients within the ﬁrst 35 days after alloHSCT
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VRE among Stem Cell Transplant Recipients 617Table 2). Three bloodstream infections were polymi-
robial, including 1 patient with coagulase-negative
taphylococcus and Lactobacillus, 1 patient with co-
gulase-negative Staphylococcus and Fusobacterium,
nd 1 patient with Lactobacillus and Klebsiella pneu-
oniae. Seven patients had blood cultures that were
hought to be contaminated by coagulase-negative
able 1. A Comparison of All Adult Allogeneic Hematopoietic Stem Ce
ugust 2004 and February 2006 Who Underwent Stool Screening for V
ound to Have VRE Stool Colonization and Those Who Developed a VR
All Patients (%
atients 92
edian age (range) 50 (23-71)
ale 52 (56.5%)
rimary disease
Acute lymphoblastic leukemia 14 (15.2%)
Acute myelogenous leukemia 37 (40.2%)
Chronic lymphocytic leukemia 1 (1.1%)
Chronic myelogenous leukemia 2 (2.2%)
Hodgkin Lymphoma 3 (3.3%)
Myelodysplastic syndrome 20 (21.7%)
Multiple myeloma 1 (1.1%)
Non-Hodgkin lymphoma 13 (14.1%)
Prolymphocytic leukemia 1 (1.1%)
igh-risk primary disease* 57 (62.0%)
cute leukemia or RAEB 62 (67.4%)
ransplant characteristics
Myeloablative conditioning regimen 80 (87.0%)
Total body irradiation >2 Gy 41 (44.6%)
Allograft T cell depletion 57 (62.0%)
Peripheral blood stem cell allograft 86 (93.5%)
HLA-matched sibling donor‡ 43 (46.7%)
RE bloodstream infection 14 (15.2%)
edian follow-up for survivors (months) 11 (3-22)
Patients with acute myelogenous leukemia in ﬁrst or second compl
myelogenous leukemia in ﬁrst chronic phase were classiﬁed as “
p  .05 compared to patients with any disease other than acute le
Patients who did not have sibling donors received allografts from
able 2. Thirty-Seven Bacterial and Fungal Organisms That Caused
4 Bloodstream Infections among Adult Allogeneic Hematopoietic Stem
ell Transplant (alloHSCT) Recipients within the First 35 Days after
ransplant
Organism Isolates (%) Day(s) after alloHSCT
nterococcus faecium 13 (35.1%) 0,3,5,5,5,5,6,6,7,8,12,20,33
lebsiella pneumoniae 4 (10.8%) 0,1,3,9
usobacterium 3 (8.1%) 3,9
oagulase-negative
Staphylococcus 3 (8.1%) 3,3,5
treptococcus mitis 3 (8.1%) 3,5,5
nterobacter cloacae 2 (5.4%) 4,4
actobacillus 2 (5.4%) 3,3
cinetobacter baumanii 1 (2.7%) 32
acillus 1 (2.7%) 1
andida kruseii 1 (2.7%) 2
andida lusitaniae 1 (2.7%) 5
nterococcus avium 1 (2.7%) 5
scherichia coli 1 (2.7%) 5
treptococcus oralis 1 (2.7%) 5bRE isolates are in light face.taphylococcus. VRE caused 14 (41.1%) of the 34
loodstream infections, making it the most common
rganism by over 3-fold (Table 2). The mean number
f days from hospitalization to bloodstream infection
id not differ between patients infected by VRE and
atients infected by other organisms (16.6 versus 13.4
ays, respectively; p  .25).
Among the 37 patients colonized with VRE, 13
34.2%) developed a VRE bloodstream infection by
ay 35 after alloHSCT (Table 3), including 10 of 27
37.0%) who had VRE isolated from the ﬁrst culture
fter admission and 3 of 10 (30.0%) found to be
olonized on subsequent culture (P  1). In compar-
son, only 1 (1.8%) of 55 patients who did not have
RE on stool culture developed a VRE bloodstream
nfection (P  .001 compared with VRE colonized).
o other demographic, disease, or treatment-related
actors were associated with an increased risk for VRE
loodstream infection. None of the 14 patients with
RE bloodstream infection had graft-versus-host dis-
ase (GVHD) at the time of their bloodstream infection.
None of the 92 study patients had1 bloodstream
nfection. Twenty (25.6%) of the 78 patients who did
ot have a VRE bloodstream infection had a blood-
tream infection caused by an organism other than
RE, compared to 0 (0.0%) of 14 who had a VRE
splant Recipients at Memorial Sloan-Kettering Cancer Center between
ycin-Resistant Enterococcus (VRE) Colonization, Those Who Were
dstream Infection
VRE Colonized (%) VRE Bloodstream Infection (%)
37 14
48 (23-68) 51 (29-68)
18 (48.6%) 6 (42.9%)
19 (51.4%) 7 (50%)
32 (86.5%)† 10 (71.4%)
36 (97.3%) 13 (92.9%)
18 (48.6%) 7 (50%)
25 (67.6%) 11 (78.6%)
34 (91.9%) 13 (92.9%)
16 (43.2%) 8 (57.1%)
13 (34.2%) 14 (100%)
13 (3-21) 9 (3-21)
ission (CR), acute lymphoblastic leukemia in ﬁrst CR, and chronic
rd” risk. All other patients were considered “high” risk.
or refractory anemia with excess blasts (RAEB).
mismatched or unrelated donors.ll Tran
ancom
E Bloo
)
ete rem
standa
ukemialoodstream infection (P  .03). Bloodstream infec-
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D. M. Weinstock et al.618ion caused by organisms other than VRE were also
ess common among the 24 patients who were colo-
ized with VRE but did not have a VRE bloodstream
nfection (12.5%) than among the 55 patients who
ere not colonized with VRE (30.9%; P  .05).
utcomes
Mortality was directly attributable to VRE blood-
tream infection in 2 (14.3%) of the 14 patients (Table 3).
RE bloodstream infection contributed to mortality
n 3 (21.4%) additional patients. Overall survival at 1
ear after alloHSCT (Figure 1A) did not differ between
atients who were not colonized with VRE and patients
ho were colonized but did not develop bloodstream
nfection (hazard ratio [HR], 0.8; 95% conﬁdence inter-
al [CI], 0.3-1.9; P  .55). Of note, patients who had
RE bloodstream infection had signiﬁcantly worse sur-
ival compared to patients without VRE bloodstream
nfection (HR, 5.1; 95% CI, 1-26; P  .05).
Four (28.5%) of 14 patients with VRE blood-
tream infection in our series had microbiologic fail-
able 3. A Description of the 14 Allogeneic Hematopoietic Stem Cell T
ancomycin-Resistant Enterococci (VRE) between August 2004 and Febr
Patient
Days of
Bacteremia
ANC on First
Day of BSI
VRE
Species Treatmen
101 7 <200/L E. faecium Linezolid/7
Daptomyc
Gentam
102 2 <200/L E. faecium Daptomyc
Linezolid/1
103 2 <200/L E. faecium Linezolid/2
104 1 <200/L E. faecium Linezolid/1
Daptomyc
105 2 <200/L E. faecium Linezolid/1
106 5 <200/L E. faecium Linezolid/3
107 1 <200/L E. faecium Linezolid/1
108 1 <200/L E. faecium Linezolid/2
Daptomyc
109 1 5000/L E. faecium Daptomyc
Linezolid/5
110 4 <200/L E. faecium Linezolid/6
Daptomyc
111 1 <200/L E. faecium Linezolid/8
Daptomyc
112 6 <200/L E. avium Linezolid/3
Ampicillin
Gentam
Dapto/3 (a
113 3 (Episode #1)
9 (Episode #2)
600/L E. faecium Daptomyc
Linezolid/1
(added)
114 7 (Episode #1)
1 (Episode #2)
<200/L E. faecium Linezolid/5
Daptomyc
ortality was attritutable to VRE bloodstream infection in patient
Patients 113 and 114 had second episodes of BSI during daptom
NC indicates absolute neutrophil count; CVC, central venous catre while receiving daptomycin (n  3) or linezolid wn  1) (Table 3). In patient 109, culture of a femoral
enous catheter tip grew VRE on day 24 and the
atient was started on daptomycin. Blood cultures at
hat time were negative. Nine days later, while still on
aptomycin, blood cultures grew VRE (daptomycin
IC  4 g/mL). Patient 113 developed a blood-
tream infection caused by VRE (daptomycin MIC 
g/mL) on day 20, received daptomycin, and
leared the bacteremia within 72 hours. Ten days
ater, while still on daptomycin, blood cultures again
rew VRE (daptomycin MIC  4 g/mL), which
ersisted for 8 days until linezolid was added. For
atient 114, VRE (daptomycin MIC  2 g/mL) was
solated from urine and blood cultures on day 3.
inezolid was started but changed 5 days later to
aptomycin resulting from pancytopenia. On the 14th
ay of daptomycin treatment, VRE (daptomycin
IC  3 g/mL) was again isolated from blood
ultures. In all 3 cases, daptomycin was dosed at 6
g/kg daily, or the equivalent dose in the setting of
enal insufﬁciency. All 3 patients died, including 2
nt Recipients Who Developed Bloodstream Infection Caused by
06 at Memorial Sloan-Kettering Cancer Center
Total Days of
Treatment
Days to CVC
Removal Alive Cause of Death
29 1, 7 Yes
16 2 No EBV posttransplant
lymphoproliferative
disorder
2 Not removed No VRE BSI
15 2 Yes
17 2 Yes
33 1 Yes
14 1 Yes
33 1 Yes
7 0 No Diffuse alveolar
hemorrhage
VRE BSI (contributing)
19 2 No Leukemia relapse
22 0 Yes Veno-occlusive disease
32 1 No VRE BSI
34 2
8
No Pneumonia
VRE BSI (contributing)
23 2
Not removed
No Drug reaction
VRE BSI (contributing)
nd 112 and contributed to mortality in patients 109, 113, and 114.
herapy. Patient 101 had 2 central venous catheters.
BV, Epstein-Barr virus; VRE, vancomycin-resistant enterococcus.ranspla
uary 20
t/Days
in 
icin/22
in/3
3
in/14
7
3
4
in/31
in/2
in/13
in/14

icin/29
dded)
in/34
5
in/18
s 103 a
ycin tithin a week after the second episode of bacteremia.
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VRE among Stem Cell Transplant Recipients 619In the 1 case of linezolid failure (patient 101),
lood cultures were initially positive (linezolid MIC 
g/mL) on day 5 after alloHSCT. A temporary ve-
ous catheter was removed and linezolid was started,
ut a tunneled venous catheter was left in place. Blood
ultures remained positive for 7 days (highest linezolid
IC  4 g/mL), until linezolid was changed to
aptomycin and gentamicin and the tunneled venous
atheter was removed.
icrobiology
Strain typing performed by PFGE (Figure 1B)
dentiﬁed 9 distinct strains among the 37 patients
olonized with VRE, with no strain present in 6
atients. Among the 13 patients with blood and stool
yping performed, 5 (35.7%) had different strains
dentiﬁed from stool and blood.
ISCUSSION
Preemptive and prophylactic approaches are
idely used in immunocompromised patients to pre-
ent infections by opportunistic pathogens, including
andida, cytomegalovirus, and pneumocystis [23]. In
ontrast, approaches to prevent or mitigate VRE in-
ection are lacking. We identiﬁed an extraordinarily
igh risk (incidence, 142/10,000 patient days) for VRE
loodstream infection by day 35 after alloHSCT
mong patients colonized with VRE. VRE blood-
tream infection was associated with a signiﬁcant re-
uction in overall survival (OS) and directly caused or
ontributed to death in over 1/3 of cases.
Vancomycin-resistant enterococcus is known to
igure 1. (A). Survival curve for patients after allogeneic hematopo
ancomycin-resistant enterococcus (VRE), those who were colon
eveloped a VRE bloodstream infection. The graph does not take in
igniﬁcantly worse for patients with VRE bloodstream infection com
or blood (B) and stool (S) isolates of VRE. Of these 7 patients, #103
solates.  indicates a DNA standard.ause nosocomial outbreaks [1,5,9,13]. However, strain vyping among the 37 patients colonized with VRE in
ur series revealed signiﬁcant heterogeneity, arguing
hat acquisition did not occur through an outbreak. In
ddition, 5 (35.7%) of 14 patients with bloodstream
nfections had different strains identiﬁed from the
tool and the blood, supporting the possibility of
olyclonal colonization. The risk for colonization
as highest among patients with acute leukemia or
igh-risk MDS. Importantly, the treatment of these
iseases prior to alloHSCT typically requires 1 or
ore hospitalizations for high-dose chemotherapy
nd broad-spectrum antibiotics for fever and neutro-
enia, presumably increasing the risk for acquiring
RE colonization.
A higher rate of VRE colonization was also re-
orted among hospitalized patients with leukemia
5.5%) at the M.D. Anderson Cancer Center, com-
ared to patients with lymphoma (2.2%) [12]. These
ates are markedly lower than in our study. However,
8% of HSC transplant recipients in the M.D. Ander-
on series who were colonized with VRE developed a
RE bloodstream infection, very similar to the 34.2%
ate we report. In fact, several studies have reported
ates of VRE bloodstream infection between 25% and
5% among colonized patients, including adult and
ediatric stem cell transplant recipients, liver trans-
lant recipients, and patients with hematologic malig-
ancies receiving chemotherapy [12,24-26], despite
igniﬁcant differences in the rates of colonization.
hus, the local epidemiology of VRE colonization
ppears to be less important in predicting VRE blood-
tream infection than the pathogenicity of VRE, in-
luding its ability to colonize and persist within intra-
em cell transplant, divided into those who were not colonized with
t did not develop a VRE bloodstream infection, and those who
unt time-dependent nature of the covariates. Survival at 1 year was
o the other 2 cohorts (P .05). (B) Pulsed-ﬁeld gel electrophoresis
#107, and #108 had different clones identiﬁed from blood and stoolietic st
ized bu
to acco
pared t
, #105,ascular catheters. It remains unclear whether the esp
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D. M. Weinstock et al.620ene, a member of the pathogenicity island found
ithin nosocomial VRE isolates, fosters the ability of
RE to form and colonize bioﬁlm [6,27].
The appropriate frequency of stool screening for
RE has not been clearly deﬁned. We elected to
creen all patients upon admission and to perform
ubsequent screening only in patients with diarrhea or
pon transfer to the intensive care unit. This approach
dentiﬁed VRE colonization prior to bloodstream infec-
ion in all but 1 case and required signiﬁcantly fewer
tool cultures than routine weekly surveillance. Stool
ulture is 100% sensitive for identifying VRE colo-
ization [28]. Thus, the 11 patients who “acquired”
RE during the alloHSCT hospitalization (10 with
ositive stool cultures and 1 with bloodstream infec-
ion without positive stool cultures) may have actually
een colonized with VRE upon admission, which sub-
equently overgrew in the presence of broad-spectrum
ntibiotics.
Some groups have reported high rates of VRE
loodstream infection among alloHSCT recipients,
ut concluded that VRE infection is simply a marker,
ather than the cause, of poor outcome [16,19]. In
hese and other studies [15-19], patients who devel-
ped VRE bloodstream infection in the early post-
ransplant period were analyzed together with patients
ho developed infection much later, frequently in the
etting of GVHD. We chose to focus solely on the
arly posttransplant period, when VRE bloodstream
nfection is closely associated with neutropenia and
ucosal damage resulting from the preparative regi-
en. If VRE bloodstream infection in this setting
ere simply a marker of higher infection risk, we
ould expect the patients with VRE bloodstream in-
ections to have high rates of bloodstream infection by
ther organisms. Instead, bloodstream infection re-
ulting from organisms other than VRE was more
ommon among patients who did not have VRE in-
ections (25.6%) than among patients with VRE in-
ections (0.0%). The lower rate argues against VRE as
marker of greater risk for infection and possibly for
protective effect from VRE colonization. The latter
s supported by the low rate (12.5%) of bloodstream
nfection from organisms other than VRE among the
4 patients who were colonized by VRE but did not
evelop a VRE infection.
In 5 (35.7%) of the 14 patients with VRE blood-
tream infection in our series, mortality was directly
ttributable to VRE infection (2 patients) or VRE
nfection contributed to mortality (3 patients). Impor-
antly, day 45 survival among patients with VRE
loodstream infection was 71.4%, compared to 96.2%
mong patients who did not have a VRE bloodstream
nfection (absolute difference, 24.8%). If VRE blood-
tream infection in the early posttransplant period
ere simply a marker for higher mortality, we would
xpect patients with VRE infections to continue to die Vt higher rates than the patients who did not have
RE bloodstream infections. Instead, the absolute dif-
erence of 25% in survival by day 45 remains
elatively constant over the subsequent 18-24 months
f follow-up, with comparable late mortality among
oth groups, presumably from factors like disease re-
apse and GVHD. Thus, patients who survive their
RE bloodstream infection appear to be at compara-
le risk for mortality from other complications as
atients who did not have a VRE bloodstream infec-
ion.
Linezolid and daptomycin are the agents used
ost frequently to treat VRE bloodstream infection.
owever, their broad spectra of activity and potential
ide effects, including myelosuppression from lin-
zolid, have contributed to a general reluctance to use
hem for prophylaxis. Importantly, 4 of 14 patients
ith VRE bloodstream infection in our series had
icrobiologic failure while receiving 1 of these agents.
n all 3 cases of daptomycin failure, the VRE isolated
uring therapy remained susceptible in vitro to dap-
omycin, arguing against a clear correlation between
aptomycin MIC and efﬁcacy in highly immunocom-
romised patients.
Our study has several shortcomings. First, the lack
f a control arm prevents any conclusions about the
irect effects of VRE colonization or VRE blood-
tream infection on survival. A randomized study is
eeded to determine whether an approach that in-
ludes: (1) routine stool screening of alloHSCT recip-
ents, (2) early isolation of colonized patients, and
3) empiric treatment of fever during neutropenia with
aptomycin or linezolid in the VRE colonized patients
an improve overall mortality. The second shortcom-
ng is the variation in approach between patients,
ncluding differences in the day that the stool isolate
as obtained and the antimicrobial therapy for VRE
loodstream infection. Third, several patients re-
eived care for their underlying malignancy at other
enters before transferring their care to our institution
or alloHSCT. Thus, we were unable to analyze the
ole of certain factors on the risk for VRE coloniza-
ion or bloodstream infection, including lifetime ex-
osure to antibiotics and lifetime days of hospitaliza-
ion. Fourth, vancomycin prophylaxis was used in 15
atients, although their rates of VRE colonization
40%) and bloodstream infection among colonized
atients (33.3%) did not differ from the group that did
ot receive vancomycin prophylaxis. Finally, the fre-
uent use of allograft T cell depletion may affect the
pplicability of our ﬁndings to other transplant centers.
In conclusion, we ﬁnd that colonization in the
etting of alloHSCT confers an extraordinarily high
isk for VRE bloodstream infection in the early post-
ransplant period, with a considerable decrement in sur-
ival. Approximately 1/3 of patients in our study were
RE colonized, 1/3 of those developed VRE blood-
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VRE among Stem Cell Transplant Recipients 621tream infection, and 1/3 of those succumbed to the
nfection. As a result of these ﬁndings, we routinely use
aptomycin or linezolid for 48 hours as empiric treat-
ent of fever and neutropenia in alloHSCT recipients
ho are colonized by VRE. Although these agents
ere associated with a high rate of microbiologic fail-
re in our patients, the high mortality of VRE blood-
tream infection in the early posttransplant period
upports the aggressive use of empiric therapy until
ulture results are available. Studies of new ap-
roaches to prevent colonization, minimize the bur-
en of VRE growth in the gastrointestinal tract, and
nhibit seeding of vascular access devices are promptly
eeded.
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